Log in to your Inderes Free account to see all free content on this page.

Lundbeck

42.54 DKK

+0.19 %

Less than 1K followers

HLUN B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

+0.19 %

+4.32 %

+15.04 %

-1.44 %

-7.72 %

+33.35 %

+22.74 %

+13.99 %

+72.93 %

Lundbeck is a pharmaceutical company. The greatest focus is found in research on psychiatric and neurotic disorders, which includes the treatment of depression, schizophrenia, Alzheimer's and Parkinson's syndrome. The company conducts research, development and distribution of medicines where the customer base can be found on a global level. The company was originally founded in 1915 and has its headquarters in Valby.

Market cap

42.36B DKK

Turnover

9.48M DKK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

13.5.

2026

Interim report Q1'26

19.8.

2026

Interim report Q2'26

11.11.

2026

Interim report Q3'26

All

Press releases

ShowingAll content types

Press release4/19/2026, 1:00 PM

H. Lundbeck A/S: Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)

Press release4/13/2026, 7:00 AM

H. Lundbeck A/S: Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

Regulatory press release3/18/2026, 12:00 PM

H. Lundbeck A/S: Lundbeck held its Annual General Meeting on 18 March 2026 at the company's registered office

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release3/16/2026, 8:00 AM

H. Lundbeck A/S: Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026

Press release3/10/2026, 8:00 AM

H. Lundbeck A/S: Lundbeck appoints Chief AI Officer

Regulatory press release3/9/2026, 9:33 AM

H. Lundbeck A/S: Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial

Regulatory press release2/18/2026, 8:32 AM

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Regulatory press release2/17/2026, 9:00 AM

To the shareholders of H. Lundbeck A/S

Regulatory press release2/12/2026, 3:39 PM

H. Lundbeck A/S: Lundbeck announces positive phase IIb top-line results with bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention

Regulatory press release2/6/2026, 10:39 AM

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Regulatory press release2/4/2026, 6:13 PM

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Regulatory press release2/4/2026, 6:50 AM

H. Lundbeck A/S: Lundbeck Annual Report 2025

Regulatory press release2/4/2026, 6:30 AM

H. Lundbeck A/S: Record 2025 performance with revenue up 13% CER and adjusted EBITDA up 24% CER positions Lundbeck for continued growth in 2026

Press release1/30/2026, 2:00 PM

H. Lundbeck A/S: Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference

Regulatory press release12/8/2025, 7:22 AM

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Press release12/6/2025, 5:00 PM

H. Lundbeck A/S: Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting

Press release12/2/2025, 7:00 AM

H. Lundbeck A/S: Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting

Regulatory press release11/26/2025, 4:23 PM

H. Lundbeck A/S: ANNOUNCEMENT FOR THE PURPOSES OF ARTICLE 17 "MAR" RULES (EU) NO. 596/2014 (INSIDE INFORMATION) AND RULE 2.8 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE "IRISH TAKEOVER RULES")

Regulatory press release11/14/2025, 11:44 AM

H. Lundbeck A/S: ANNOUNCEMENT FOR THE PURPOSES OF RULE 2.12 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE "IRISH TAKEOVER RULES") AND MAR ARTICLE 17 (INSIDE INFORMATION)

Press release11/14/2025, 7:55 AM

H. Lundbeck A/S: Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.